Methylphenidate for attention deficit hyperactivity disorder and drug relapse in criminal offenders with substance dependence: a 24-week randomized placebo-controlled trial

AIM: To test the efficacy and safety of osmotic release oral system (OROS) methylphenidate (MPH) in doses up to 180 mg/day to treat attention deficit hyperactivity disorder (ADHD) and prevent any drug relapse in individuals with a co-diagnosis of ADHD and amphetamine dependence. DESIGN: Randomized p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Addiction
Main Authors: Konstenius, Maija, Jayaram-Lindström, Nitya, Guterstam, Joar, Beck, Olof, Philips, Björn, Franck, Johan
Formato: Artigo
Idioma:Inglês
Publicado em: BlackWell Publishing Ltd 2014
Assuntos:
Research Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226329/
https://ncbi.nlm.nih.gov/pubmed/24118269
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/add.12369
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados